Progression from F3 to cirrhosis occurred in roughly one year, contrasting STELLAR’s 13% over four years and suggesting trials may underrepresent real-world risk. Among compensated cirrhosis, 29.7% ...

Findings from insitro's lead therapeutic CTRO-1013 program demonstrate that liver-targeted silencing of IRS1 lowered circulatory biomarkers associated with fibrosis progression and hepatocyte injury ...

Altimmune, Inc. (NASDAQ:ALT) is one of the small-cap stocks with potential to rise 1000 percent. The company’s lead drug candidate, pemvidutide, is being developed for MASH, a serious liver disease ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Novo Nordisk presented new Phase 3 ESSENCE data on ...

Gene expression analysis from the STAM mouse model attributes Thykamine™ with dose-dependent anti-MASH, anti-inflammatory and anti-fibrosis molecular effects in liver QUÉBEC, Feb. 12, 2026 /PRNewswire ...

Altimmune (NASDAQ:ALT) lost ~64% in the premarket on Thursday after the company announced a mixed readout from a mid-stage trial for pemvidutide, its experimental therapy for a liver condition known ...

QUEBEC, Feb. 19, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced positive results from a follow-up preclinical study evaluating ...

Secondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB with Rezdiffra ® (resmetirom) Analysis of two-year data in ...

A Boehringer Ingelheim drug in development for weight loss now has data from a separate mid-stage clinical trial showing dramatic reductions across several measures of a fatty liver disease whose ...

Concurrent improvement across key non-invasive tests underscores convergence of pemvidutide effects on MASH disease activity and fibrosis AI-based digital pathology analyses further demonstrate ...